Hussman Strategic Advisors Inc. Takes Position in Stoke Therapeutics, Inc. $STOK

Key Points

• Hussman Strategic Advisors acquired 63,000 shares of Stoke Therapeutics in Q4, a new stake valued at about $2.0 million representing roughly 0.11% of the company.
• Analysts are largely positive: STOK has a consensus rating of "Moderate Buy" with an average target of $41.83, and several firms have raised price targets (Canaccord to $60; Wolfe, BTIG, Wedbush with buy/outperform calls).
• Insiders have been net sellers—69,699 shares (~$2.53 million) sold in the last 90 days (insiders own 9.5%)—and the company reported a Q1 loss (EPS -$0.97) while trading near $33 with a market cap of about $2.06 billion.

Hussman Strategic Advisors Inc. acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 63,000 shares of the company's stock, valued at approximately $2,000,000. Hussman Strategic Advisors Inc. owned approximately 0.11% of Stoke Therapeutics at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the business. Strs Ohio lifted its holdings in shares of Stoke Therapeutics by 9.4% during the 4th quarter. Strs Ohio now owns 7,000 shares of the company's stock valued at $222,000 after purchasing an additional 600 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Stoke Therapeutics by 31.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company's stock valued at $88,000 after purchasing an additional 658 shares in the last quarter. Generali Investments Management Co LLC lifted its holdings in shares of Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company's stock valued at $78,000 after purchasing an additional 718 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Stoke Therapeutics by 5.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock valued at $162,000 after purchasing an additional 1,149 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of Stoke Therapeutics by 12.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company's stock valued at $296,000 after purchasing an additional 1,313 shares in the last quarter.

Analysts Set New Price Targets

Several research firms have recently weighed in on STOK. Wolfe Research initiated coverage on Stoke Therapeutics in a report on Monday, February 23rd. They set an "outperform" rating and a $40.00 price objective on the stock. BTIG Research restated a "buy" rating and issued a $39.00 target price on shares of Stoke Therapeutics in a research note on Thursday, March 19th. Wedbush boosted their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the company an "outperform" rating in a research note on Tuesday, March 17th. Weiss Ratings restated a "hold (c)" rating on shares of Stoke Therapeutics in a research note on Friday, April 10th. Finally, Canaccord Genuity Group boosted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, March 20th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $41.83.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Barry Ticho sold 1,461 shares of Stoke Therapeutics stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $29.99, for a total transaction of $43,815.39. Following the sale, the insider directly owned 40,702 shares in the company, valued at approximately $1,220,652.98. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jason Hoitt sold 1,931 shares of Stoke Therapeutics stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total value of $60,517.54. Following the sale, the insider owned 10,276 shares in the company, valued at $322,049.84. This trade represents a 15.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 69,699 shares of company stock valued at $2,526,714 in the last ninety days. 9.50% of the stock is owned by corporate insiders.

Stoke Therapeutics Trading Up 1.1%

Shares of STOK stock opened at $33.08 on Friday. The stock has a 50-day moving average of $34.48 and a 200-day moving average of $32.08. Stoke Therapeutics, Inc. has a 1-year low of $8.30 and a 1-year high of $40.22. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of -275.64 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 16th. The company reported ($0.97) EPS for the quarter. Stoke Therapeutics had a negative return on equity of 2.05% and a negative net margin of 3.73%.The business had revenue of $1.40 million for the quarter. Sell-side analysts forecast that Stoke Therapeutics, Inc. will post -3.41 earnings per share for the current year.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company's lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.